On September 16, 2008, the U.S. Food and Drug Administration (
Site Search
Showing 61 - 70 of 99 results
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
1 min read
The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.
News
|
|
3 min read